CEP89

Across TCGA pan-cancer cohorts, CEP89 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CEP89 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CEP89 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CEP89 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

LSCC and CCRCC are the cancer types where CEP89 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	II,III,IV	0.322	1.000	.024	6	view →
CCRCC	DFS	Median	II,III,IV	0.842	0.540	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CEP89–LSCC (DFS)

Open the LSCC breakdown →